- Home
- TERN vs RIGL Comparison
TERN vs RIGL Comparison
Compare TERN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- RIGL
- Stock Information
- Founded
- TERN 2017
- RIGL 1996
- Country
- TERN United States
- RIGL United States
- Employees
- TERN N/A
- RIGL N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- RIGL Health Care
- Exchange
- TERN Nasdaq
- RIGL Nasdaq
- Market Cap
- TERN 298.1M
- RIGL 298.0M
- IPO Year
- TERN 2021
- RIGL 2000
- Fundamental
- Price
- TERN $2.71
- RIGL $17.03
- Analyst Decision
- TERN Buy
- RIGL Buy
- Analyst Count
- TERN 5
- RIGL 5
- Target Price
- TERN $18.38
- RIGL $36.80
- AVG Volume (30 Days)
- TERN 1.3M
- RIGL 222.1K
- Earning Date
- TERN 05-12-2025
- RIGL 05-06-2025
- Dividend Yield
- TERN N/A
- RIGL N/A
- EPS Growth
- TERN N/A
- RIGL N/A
- EPS
- TERN N/A
- RIGL 0.99
- Revenue
- TERN N/A
- RIGL $179,278,000.00
- Revenue This Year
- TERN N/A
- RIGL $12.53
- Revenue Next Year
- TERN N/A
- RIGL $15.68
- P/E Ratio
- TERN N/A
- RIGL $17.36
- Revenue Growth
- TERN N/A
- RIGL 54.71
- 52 Week Low
- TERN $1.87
- RIGL $7.48
- 52 Week High
- TERN $11.40
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- TERN 49.80
- RIGL 40.01
- Support Level
- TERN $2.22
- RIGL $16.05
- Resistance Level
- TERN $2.43
- RIGL $17.67
- Average True Range (ATR)
- TERN 0.26
- RIGL 1.24
- MACD
- TERN 0.08
- RIGL 0.03
- Stochastic Oscillator
- TERN 83.25
- RIGL 39.46
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.